6533b86dfe1ef96bd12ca9b4

RESEARCH PRODUCT

Identification and Successful Negotiation of a Metabolic Checkpoint in Direct Neuronal Reprogramming

Susan GasconMagdalena GötzMartin IrmlerFelipe OrtegaFelipe OrtegaFelipe OrtegaDavid PetrikStephen P. RobertsonJohannes BeckersGianluca Luigi RussoAditi DeshpandeMarisa KarowCarsten BerndtMarcus ConradGiacomo MasserdottiTimm SchroederBenedikt BerningerBenedikt BerningerJosé Pedro Friedmann AngeliChristophe HeinrichElisa Murenu

subject

0301 basic medicineGeneticsProgrammed cell deathCell typeCellular Reprogramming TechniquesMutantCell BiologyBiologyIn vitroCell biology03 medical and health sciencesTransduction (genetics)030104 developmental biologyIn vivoGeneticsMolecular MedicineReprogramming

description

Despite the widespread interest in direct neuronal reprogramming, the mechanisms underpinning fate conversion remain largely unknown. Our study revealed a critical time point after which cells either successfully convert into neurons or succumb to cell death. Co-transduction with Bcl-2 greatly improved negotiation of this critical point by faster neuronal differentiation. Surprisingly, mutants with reduced or no affinity for Bax demonstrated that Bcl-2 exerts this effect by an apoptosis-independent mechanism. Consistent with a caspase-independent role, ferroptosis inhibitors potently increased neuronal reprogramming by inhibiting lipid peroxidation occurring during fate conversion. Genome-wide expression analysis confirmed that treatments promoting neuronal reprogramming elicit an anti-oxidative stress response. Importantly, co-expression of Bcl-2 and anti-oxidative treatments leads to an unprecedented improvement in glial-to-neuron conversion after traumatic brain injury in vivo, underscoring the relevance of these pathways in cellular reprograming irrespective of cell type in vitro and in vivo.

https://doi.org/10.1016/j.stem.2015.12.003